🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. Hormone replacement therapy (estrogen/progestin)

    United Therapeutics Europe Ltd

    Anorexia Nervosa

    phase 3 small molecule completed

    1 trial

  2. Household-based water treatment with NADCC tablets

    United Therapeutics Europe Ltd

    Diarrhoea

    phase 3 other completed

    1 trial

  3. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  4. Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)

    Takeda

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  5. Humira 40 mg solution for injection in pre-filled syringe, ORENCIA 50 mg solution for injection in pre-filled syringe, Tyenne 162mg/0.9ml solution for injection in pre-filled syringe, Humira 20 mg solution for injection in pre-filled syringe, XELJANZ 1 mg/mL oral solution, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, XELJANZ 5 mg film-coated tablets, ORENCIA 87.5 mg solution

    The George Institute

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  6. Hydrocodone ER

    Teva Pharma GmbH

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  7. Hydrocodone ER

    Teva Pharma GmbH

    Chronic Pain

    phase 3 small molecule completed

    2 trials

  8. IAC regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  9. IAE0972+ Methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NPC

    phase 3 mab active

    1 trial

  10. IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules

    Partner Therapeutics Limited

    Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.

    phase 3 small molecule active

    1 trial

  11. IBRANCE 125 mg film-coated tablets, Placebo Giredestrant, IBRANCE 100 mg hard capsules, RO7197597, Placebo Letrozole, IBRANCE 75 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, Femara® 2,5 mg Filmtabletten, IBRANCE 100 mg film-coated tablets

    Hoffmann-La Roche

    ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

    phase 3 small molecule active

    1 trial

  12. IBRANCE 75 mg film-coated tablets, GOSERELIN ACETATE, Placebo to match camizestrant, Placebo to match anastrozole, camizestrant, ABEMACICLIB, Placebo to match letrozole, IBRANCE 100 mg film-coated tablets, Arimidex® 1 mg Filmtabletten, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, LETROZOLE, LEUPRORELIN ACETATE, ABEMACICLIB, Camizestrant, ABEMACICLIB

    AstraZeneca AB

    Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  13. IBRUTINIB, PIRTOBRUTINIB, PIRTOBRUTINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  14. ICT-107

    Chongqing Precision Biotech Co., Ltd

    Glioblastoma Multiforme

    phase 3 mab completed

    2 trials

  15. IKT-001

    Inhibikase Therapeutics

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  16. IL-1Ra

    United Therapeutics Europe Ltd

    Subarachnoid Hemorrhage

    phase 3 small molecule active

    1 trial

  17. IM JZP-458

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  18. IMBRUVICA 140 mg hard capsules, Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules

    Lacuna Pharma Pty Ltd

    High Risk Chronic Lymphocytic Leukaemia

    phase 3 small molecule active

    1 trial

  19. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Wuhan Createrna Science and Technology Co., Ltd

    Small-cell lung cancer, extensive stage

    phase 3 small molecule active

    1 trial

  20. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  21. IMFINZI 50 mg/mL concentrate for solution for infusion., DURVALUMAB, MYCOPHENOLATE MOFETIL, Placebo, OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., INFLIXIMAB

    AstraZeneca AB

    Non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  22. IMFINZI 50 mg/mL concentrate for solution for infusion., Futibatinib, Zercepac 150 mg powder for concentrate for solution for infusion., Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets, JZP598, Zejula 100 mg hard capsules, Nerlynx 40 mg film-coated tablets, IVOSIDENIB, CISPLATIN, PEMBROLIZUMAB, GEMCITABINE

    Ningbo Cancer Hospital

    Advanced Biliary Cancer (ABC)

    phase 3 small molecule active

    1 trial

  23. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., OXALIPLATIN, GEMCITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with hepatocellular carcinoma with high tumor burden.

    phase 3 small molecule active

    1 trial

  24. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., Mycophenolate Mofetil 500 mg film-coated tablets, Nexavar 200 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Advanced hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources